Cargando…
Practice change in the management of metastatic urothelial carcinoma after ASCO 2020
Metastatic urothelial carcinoma (mUC) is an incurable and aggressive disease. In the past decades there have been few effective treatment options that have impacted the prognosis of mUC patients. However, in the last few years, several drugs have emerged as new treatment choices that are changing th...
Autores principales: | Gajate, Pablo, Torres-Jiménez, Javier, Bueno-Bravo, Carolina, Couñago, Felipe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769717/ https://www.ncbi.nlm.nih.gov/pubmed/33437659 http://dx.doi.org/10.5306/wjco.v11.i12.976 |
Ejemplares similares
-
Update on the treatment of metastatic renal cell carcinoma
por: Medina López, Rafael Antonio, et al.
Publicado: (2022) -
Highlights of ASCO 2023
por: Neugut, Alfred I, et al.
Publicado: (2023) -
ASCO 2018: highlights of urothelial cancer and prostate cancer
por: Pichler, Renate, et al.
Publicado: (2018) -
ASCO 2020: highlights in breast cancer
por: Bartsch, Rupert
Publicado: (2021) -
ASCO update—best of the best
por: Petzer, Andreas
Publicado: (2022)